CO2018001256A2 - Anticuerpos anti-cd154 y métodos para producir los mismos - Google Patents
Anticuerpos anti-cd154 y métodos para producir los mismosInfo
- Publication number
- CO2018001256A2 CO2018001256A2 CONC2018/0001256A CO2018001256A CO2018001256A2 CO 2018001256 A2 CO2018001256 A2 CO 2018001256A2 CO 2018001256 A CO2018001256 A CO 2018001256A CO 2018001256 A2 CO2018001256 A2 CO 2018001256A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- seq
- further provides
- amino acid
- specifically binds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención refiere un anticuerpo antagonista o una porción de unión al antígeno de este que se une específicamente a CD154 humana de SEQ ID NO: 1, que comprende una región determinante de complementariedad de cadena pesada (HCDR) 1 de SEQ ID NO: 17 (SYGIS), una HCDR2 de SEQ ID NO: 23 (WISPIFGNTNYAQKFQG) y una HCDR3 de SEQ ID NO: 30 (SRYYGDLDY) o una variante de este como se describe en este documento. También, se proporciona un anticuerpo antagonista aislado que se une específicamente a CD154 de SEQ ID NO: 1, en donde el anticuerpo comprende ciertas secuencias de aminoácidos de VH y VL como se describe en la presente descripción. La invención proporciona, además, un anticuerpo antagonista aislado que se une específicamente a CD154 de SEQ ID NO: 1, en donde el anticuerpo comprende ciertas secuencias de aminoácidos de HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 y LCDR3 como se describe en la presente descripción. Adicionalmente, la invención proporciona, además, un anticuerpo antagonista aislado o una porción de unión al antígeno de este que se une específicamente a CD154 de SEQ ID NO: 1, en donde CD154 es un homotrímero y el anticuerpo se une a un primer monómero de CD154 en el homotrímero dentro de los residuos de aminoácidos 182-207 de CD154 y a un segundo monómero de CD154 en el homotrímero dentro de los residuos de aminoácidos 176-253 de CD154, en donde la numeración de residuos es de acuerdo con la SEQ ID NO: 1. La invención proporciona, además, un inmunoconjugado que comprende el anticuerpo o la porción de unión al antígeno del anticuerpo de la invención unido a un agente terapéutico o a un agente de formación de imágenes. La invención proporciona, además, una composición farmacéutica que comprende el anticuerpo de la invención y un portador farmacéuticamente aceptado, así como un polinucleótido que codifica la VH del anticuerpo de la invención, la VL del anticuerpo de la invención, o la VH y la VL del anticuerpo de lainvención. La invención proporciona, además, un vector que comprende el polinucleótido de la invención, así como una célula huésped que comprende el vector de la invención. Adicionalmente, la invención proporciona un método para producir un anticuerpo, así como un anticuerpo antiidiotípico que se une al anticuerpo de la invención, y un estuche que comprende el anticuerpo de la invención.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562201150P | 2015-08-05 | 2015-08-05 | |
US201662367660P | 2016-07-28 | 2016-07-28 | |
PCT/US2016/045574 WO2017024146A1 (en) | 2015-08-05 | 2016-08-04 | Anti-cd154 antibodies and methods of using them |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018001256A2 true CO2018001256A2 (es) | 2018-05-10 |
Family
ID=57944010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0001256A CO2018001256A2 (es) | 2015-08-05 | 2018-02-07 | Anticuerpos anti-cd154 y métodos para producir los mismos |
Country Status (26)
Country | Link |
---|---|
US (2) | US10669343B2 (es) |
EP (1) | EP3331563B1 (es) |
JP (2) | JP7049988B2 (es) |
KR (1) | KR20180030917A (es) |
CN (2) | CN114605549A (es) |
AU (1) | AU2016301361B2 (es) |
BR (1) | BR112018002319A2 (es) |
CA (1) | CA2994825A1 (es) |
CL (1) | CL2018000298A1 (es) |
CO (1) | CO2018001256A2 (es) |
EA (1) | EA201890434A1 (es) |
EC (1) | ECSP18008922A (es) |
ES (1) | ES2944982T3 (es) |
GT (1) | GT201800034A (es) |
HK (1) | HK1256804A1 (es) |
IL (2) | IL293065A (es) |
MA (1) | MA45573A (es) |
MX (1) | MX2018001522A (es) |
MY (1) | MY188405A (es) |
NI (1) | NI201800017A (es) |
PE (1) | PE20180802A1 (es) |
PH (1) | PH12018500203A1 (es) |
SG (1) | SG10201913275QA (es) |
SV (1) | SV2018005624A (es) |
UA (1) | UA123398C2 (es) |
WO (1) | WO2017024146A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018001522A (es) * | 2015-08-05 | 2018-03-15 | Janssen Biotech Inc | Anticuerpos anti-cd154 y metodos de uso de estos. |
PL3331891T3 (pl) | 2015-08-05 | 2022-03-28 | Eisai R&D Management Co., Ltd. | Sposób wytwarzania zasadniczo czystego diastereoizomerycznie oligomeru amidofosforanowego, oligomer amidofosforanowy wytworzony takim sposobem oraz kompozycja farmaceutyczna zawierająca taki oligomer amidofosforanowy |
CN108473561B (zh) | 2015-11-27 | 2022-12-16 | 埃博灵克斯股份有限公司 | 抑制cd40l的多肽 |
AU2019347730A1 (en) * | 2018-09-24 | 2021-03-25 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-CD154 antibody |
EP3998282A4 (en) * | 2019-07-08 | 2023-08-09 | Progen Co., Ltd. | NEW FUSION PROTEIN AND ITS USE |
US20230078330A1 (en) * | 2020-01-27 | 2023-03-16 | Vanderbilt University | Human anti-dengue antibodies and methods of use therefor |
IL299942A (en) * | 2020-07-28 | 2023-03-01 | Lg Chemical Ltd | Anti-LILRB1 antibody and its uses |
CN115586338A (zh) * | 2022-09-20 | 2023-01-10 | 杭州赛基生物科技有限公司 | 用于检测可溶性细胞因子受体的试剂盒及其制备方法 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US226A (en) | 1837-06-03 | Samuel goss | ||
US7709A (en) | 1850-10-08 | Chas S Gaylord | Improved spring-grapple | |
US541606A (en) | 1895-06-25 | Sealed package | ||
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DK0667901T4 (da) | 1991-10-25 | 2008-11-10 | Immunex Corp | Hidtil ukendt cytokin |
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
DK0672141T3 (da) | 1992-10-23 | 2003-06-10 | Immunex Corp | Fremgangsmåder til fremstilling af opløselige, oligomere proteiner |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
IL110852A (en) | 1993-09-02 | 1999-05-09 | Dartmouth College | Methods of prolonged suppression of humoral activity |
EP0721346B1 (en) | 1993-09-02 | 1998-06-10 | Trustees of Dartmouth College | Methods for inducing antigen-specific t cell tolerance |
AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
PT832229E (pt) | 1995-06-07 | 2004-06-30 | Immunex Corp | Muteina de cd40l |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
NL1003537C2 (nl) | 1996-07-08 | 1998-01-12 | Holland Railconsult B V | Werkwijze voor het vervaardigen van een gebogen beglazing. |
AU735592B2 (en) | 1997-05-17 | 2001-07-12 | Biogen Idec Ma Inc. | Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
CN100352497C (zh) | 1998-04-03 | 2007-12-05 | 达特茅斯学院理事 | 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫 |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
GB9915653D0 (en) | 1999-07-06 | 1999-09-01 | Bruce Terry | Hose clamp |
AU1072701A (en) | 1999-10-04 | 2001-05-10 | Chiron Corporation | Cd40 antagonist for treating psoriasis |
AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
AU2004253868B2 (en) | 2003-06-13 | 2011-06-16 | Biogen Ma Inc. | Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
WO2006033702A2 (en) | 2004-07-26 | 2006-03-30 | Biogen Idec Ma Inc. | Anti-cd154 antibodies |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
ES2395953T3 (es) | 2005-01-26 | 2013-02-18 | Amgen Fremont Inc. | Anticuerpos frente a interleucina-1 beta |
TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
WO2006125201A2 (en) | 2005-05-19 | 2006-11-23 | Centocor, Inc. | Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses |
US8114964B2 (en) | 2005-05-19 | 2012-02-14 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
CL2007002567A1 (es) * | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
KR101120699B1 (ko) | 2006-11-20 | 2012-03-22 | 나노스텔라 인코포레이티드 | 금속 나노입자를 함유하는 불균질 촉매의 제조방법 |
CN103214577B (zh) | 2007-03-22 | 2015-09-02 | 生物基因Ma公司 | 特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途 |
AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
EP2231904B1 (en) | 2007-12-19 | 2016-01-13 | Janssen Biotech, Inc. | Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods |
SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
KR20110014607A (ko) | 2008-04-29 | 2011-02-11 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
EP2347038A4 (en) | 2008-10-14 | 2013-06-12 | Janssen Biotech Inc | METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
EA201890907A1 (ru) | 2009-11-30 | 2020-04-30 | Янссен Байотек, Инк. | МУТИРОВАННЫЕ Fc АНТИТЕЛА С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ |
US20110206672A1 (en) | 2010-02-25 | 2011-08-25 | Melvyn Little | Antigen-Binding Molecule And Uses Thereof |
MX353144B (es) | 2010-04-20 | 2017-12-20 | Genmab As | Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas. |
EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
US8795950B2 (en) | 2010-06-30 | 2014-08-05 | Jonghan Choi | Method of improving print performance in flexographic printing plates |
EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
EP2444101A1 (en) | 2010-10-21 | 2012-04-25 | Universitätsklinikum Freiburg | Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis |
US20140121123A1 (en) | 2010-10-29 | 2014-05-01 | Kevin Caili Wang | Methods for diversifying antibodies, antibodies derived therefrom and uses thereof |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
PL2654780T3 (pl) | 2010-12-23 | 2017-07-31 | Janssen Biotech, Inc | Aktywne mutanty przeciwciała fc odporne na proteazy |
MX2013010011A (es) | 2011-03-01 | 2014-10-24 | Amgen Inc | Agentes de unión biespecífica. |
US8852597B2 (en) * | 2011-04-04 | 2014-10-07 | The Trustees Of Dartmouth College | Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
AU2012323316B2 (en) | 2011-10-11 | 2017-08-10 | Viela Bio, Inc. | CD40L-specific Tn3-derived scaffolds and methods of use thereof |
EA030852B1 (ru) | 2011-10-13 | 2018-10-31 | Бристол-Майерс Сквибб Компани | Полипептиды антител, которые вызывают антагонизм cd40l |
KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
PT3653049T (pt) | 2012-12-14 | 2023-11-14 | Omniab Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
MX2018001522A (es) * | 2015-08-05 | 2018-03-15 | Janssen Biotech Inc | Anticuerpos anti-cd154 y metodos de uso de estos. |
US10651781B2 (en) | 2017-08-24 | 2020-05-12 | Corning Incorporated | Glass roof shingle |
-
2016
- 2016-08-04 MX MX2018001522A patent/MX2018001522A/es unknown
- 2016-08-04 ES ES16833880T patent/ES2944982T3/es active Active
- 2016-08-04 UA UAA201802170A patent/UA123398C2/uk unknown
- 2016-08-04 JP JP2018505712A patent/JP7049988B2/ja active Active
- 2016-08-04 MY MYPI2018700407A patent/MY188405A/en unknown
- 2016-08-04 WO PCT/US2016/045574 patent/WO2017024146A1/en active Application Filing
- 2016-08-04 SG SG10201913275QA patent/SG10201913275QA/en unknown
- 2016-08-04 US US15/228,582 patent/US10669343B2/en not_active Expired - Fee Related
- 2016-08-04 BR BR112018002319-1A patent/BR112018002319A2/pt active Search and Examination
- 2016-08-04 CN CN202210426273.7A patent/CN114605549A/zh active Pending
- 2016-08-04 KR KR1020187005880A patent/KR20180030917A/ko not_active Application Discontinuation
- 2016-08-04 CA CA2994825A patent/CA2994825A1/en active Pending
- 2016-08-04 MA MA045573A patent/MA45573A/fr unknown
- 2016-08-04 AU AU2016301361A patent/AU2016301361B2/en not_active Ceased
- 2016-08-04 EP EP16833880.4A patent/EP3331563B1/en active Active
- 2016-08-04 PE PE2018000170A patent/PE20180802A1/es unknown
- 2016-08-04 CN CN201680046010.6A patent/CN107921128B/zh active Active
- 2016-08-04 EA EA201890434A patent/EA201890434A1/ru unknown
- 2016-08-04 IL IL293065A patent/IL293065A/en unknown
-
2018
- 2018-01-18 IL IL256997A patent/IL256997B/en unknown
- 2018-01-25 PH PH12018500203A patent/PH12018500203A1/en unknown
- 2018-02-01 CL CL2018000298A patent/CL2018000298A1/es unknown
- 2018-02-02 NI NI201800017A patent/NI201800017A/es unknown
- 2018-02-02 GT GT201800034A patent/GT201800034A/es unknown
- 2018-02-05 SV SV2018005624A patent/SV2018005624A/es unknown
- 2018-02-07 EC ECIEPI20188922A patent/ECSP18008922A/es unknown
- 2018-02-07 CO CONC2018/0001256A patent/CO2018001256A2/es unknown
- 2018-12-11 HK HK18115888.3A patent/HK1256804A1/zh unknown
-
2020
- 2020-04-21 US US16/853,786 patent/US11421037B2/en active Active
-
2021
- 2021-12-24 JP JP2021211010A patent/JP2022058414A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018001256A2 (es) | Anticuerpos anti-cd154 y métodos para producir los mismos | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
PE20081503A1 (es) | Miembros de union para il-6 | |
PE20121360A1 (es) | Anticuerpos neutralizadores contra el receptor de prolactina | |
NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
PE20141706A1 (es) | Anticuerpos de union a trombina y usos del mismo | |
PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
AR078377A1 (es) | Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso | |
CL2010000470A1 (es) | Anticuerpo que se une a efrina-b2 que comprende la region variable de la cadena liviana y pesada bvr-l1, hvr-l2, hvr-h1, hvr-h2 y hvr-h3; polinucleotido que codifica dicho anticuerpo; vector y celula huesped que comprende al polinucleotido; metodo para elaborar el anticuerpo, detectar efrina-b2; y uso de dicho anticuerpo. |